---
title: "Zanzalintinib (XL092) in Metastatic colorectal cancer: Product information and disease description"
description: "Formulary evidence on Zanzalintinib (XL092) in Metastatic colorectal cancer: Product information and disease description. Covers Product description and Place of product in therapy. 72 evidence topics quoted from 53 sources."
canonical: "https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Zanzalintinib (XL092) in Metastatic colorectal cancer: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Investigational status

> “Zanzalintinib is an investigational agent that is not approved for any use”

Source: [Exelixis STELLAR-303 update announcement (2026)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-provides-update-phase-3-stellar-303-trial-evaluating)

<a id="topic-2.1.1-2"></a>

##### Investigational-use disclaimer

> “The safety and efficacy of these investigational compounds and/or investigational uses have not been established.”

Source: [Exelixis clinical trials pipeline](https://www.exelixis.com/clinical-trials-pipeline/)

<a id="topic-2.1.1-3"></a>

##### Regulatory status: Under review; NDA submitted December 2025

> “In December 2025, we submitted a New Drug Application (NDA) to the FDA for zanzalintinib in combination with atezolizumab”

Source: [Exelixis first quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000059/exel-20260403.htm)

<a id="topic-2.1.1-4"></a>

##### Updated FDA target action date

> “The updated Prescription Drug User Fee Act action date is March 3, 2027.”

Source: [Exelixis Form 8-K (2026)](https://ir.exelixis.com/static-files/0eed47bb-77b5-4c6e-ba9b-99a95320f1c0)

<a id="topic-2.1.1-5"></a>

##### Launch

No evidence found.

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Exelixis

> “Exelixis’ new drug application (NDA) for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer”

Source: [Exelixis Form 8-K (2026)](https://ir.exelixis.com/static-files/0eed47bb-77b5-4c6e-ba9b-99a95320f1c0)

<a id="topic-2.1.2.1-2"></a>

###### Manufacturer, compound identifier, and drug class

> “XL092; Next-generation TKI targeting MET/ VEGFR/AXL/MER”

Source: [Exelixis clinical trials pipeline](https://www.exelixis.com/clinical-trials-pipeline/)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational tablet formulation and strengths

| Registry field | Quoted record |
| --- | --- |
| Pharmaceutical form | “Film-coated tablet” |
| Investigational salt | “XL092 hemifumarate” |
| Tablet strength, mg | “100” |
| Tablet strength, mg | “60” |
| Tablet strength, mg | “40” |

Source: [EU Clinical Trials Register EudraCT 2021-003243-21](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003243-21/ES)

<a id="topic-2.1.2.2-2"></a>

###### Cayman Chemical research-reagent safety data sheet

> “CAS Number: 2367004-54-2”
> “This product is for research use - Not for human or veterinary diagnostic or therapeutic use.”

Source: [Cayman Chemical (2025)](https://cdn.caymanchem.com/cdn/msds/37749m.pdf)

<a id="topic-2.1.2.2-3"></a>

###### Commercial formulation

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Receptor tyrosine kinase inhibitor classification

> “An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs)”

Source: [National Cancer Institute Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/zanzalintinib)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Proposed indication and prior treatment requirements

> “adult patients with metastatic colorectal cancer”
> “previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-epidermal growth factor receptor (EGFR) therapy.”

Source: [Exelixis new drug application acceptance announcement (2026)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-us-fda-accepted-new-drug-application)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Receptor targets

> “Upon oral administration, zanzalintinib targets and binds to c-Met, VEGFR2, AXL and MER, and prevents their RTK activity.”

Source: [National Cancer Institute Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/zanzalintinib)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical macrophage findings

> “XL092 promoted M2 to M1 repolarization of macrophages in vitro and inhibited primary human macrophage efferocytosis in a dose-dependent manner.”

Source: [Hsu et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9890135/)

<a id="topic-2.1.2.6.2-2"></a>

###### Preclinical VEGFR2 phosphorylation in murine lungs

> “a 96% inhibition of VEGFR2 phosphorylation in murine lungs.”

Source: [Hsu et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9890135/)

Additional sources: [Hsu et al. (2021)](https://aacrjournals.org/mct/article/20/12_Supplement/P248/676008/Abstract-P248-The-tyrosine-kinase-inhibitor-XL092)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Pharmacokinetic half-life

> “Zanzalintinib has a pharmacokinetic half-life of approximately one day, supporting once-daily dosing”

Source: [Exelixis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm)

<a id="topic-2.1.2.6.3-2"></a>

###### Preliminary median terminal half-life

> “21 hours”

Source: [Patnaik et al. (2021)](https://doi.org/10.1136/jitc-2021-sitc2021.513)

Additional sources: [Yu et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39099411/)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### STELLAR-303 protocol exclusion: pregnancy and lactation

> “Pregnant or lactating females.”

Source: [EU Clinical Trials Register EudraCT 2021-003243-21](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003243-21/ES)

<a id="topic-2.1.2.8-2"></a>

###### Approved special-population dosing instructions

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Zanzalintinib

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Zanzalintinib on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### STELLAR-303 investigational dosing and administration

| Trial arm | Direct quotation |
| --- | --- |
| Zanzalintinib plus atezolizumab | “XL092 100 mg PO QD + atezolizumab 1200 mg IV Q3W” |
| Regorafenib | “regorafenib 160 mg PO QD (21 days/28-day cycle)” |

Source: [ASCO (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.TPS3630)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Registry route of zanzalintinib administration

> “Oral use”

Source: [EU Clinical Trials Register EudraCT 2021-003243-21](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003243-21/ES)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Access to investigational treatment

> “Early access is only available in limited circumstances for certain types of patients for which no other treatment options exist.”

Source: [Exelixis access to investigational therapies policy](https://www.exelixis.com/access-to-investigational-therapies/)

<a id="topic-2.1.2.11-2"></a>

###### Commercial distribution arrangements and zanzalintinib-specific patient assistance

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Combination therapy in the submitted application

> “zanzalintinib in combination with atezolizumab”

Source: [Exelixis first quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000059/exel-20260403.htm)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Zanzalintinib on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Product-specific effects on healthcare quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Related immunotherapy combinations: LEAP-017, lenvatinib plus pembrolizumab versus standard of care

> “there was no statistically significant improvement in OS after lenvatinib plus pembrolizumab treatment versus SOC.”

Source: [Kawazoe et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11328923/)

<a id="topic-2.1.2.14-2"></a>

###### Related immunotherapy combinations: IMblaze370, atezolizumab with or without cobimetinib versus regorafenib

> “IMblaze370 did not meet its primary endpoint of improved overall survival”

Source: [Eng et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31003911/)

Additional sources: [Saeed et al. (2024a)](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1068442); [Strohbehn et al. (2026)](https://ascopubs.org/doi/10.1200/OA-25-00112)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition of colorectal cancer

> “Colorectal cancer is a disease that happens when cells in the colon or rectum grow out of control.”

Source: [Centers for Disease Control and Prevention about colorectal cancer page](https://www.cdc.gov/colorectal-cancer/about/index.html)

<a id="topic-2.2.1.1-2"></a>

###### Risk factors

> “Your risk of getting colorectal cancer increases as you get older.”
> “A personal or family history of colorectal cancer or colorectal polyps.”

Source: [Centers for Disease Control and Prevention colorectal cancer risk factors page](https://www.cdc.gov/colorectal-cancer/risk-factors/index.html)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Metastatic colorectal cancer

<a id="topic-2.2.1.2.1-1"></a>

###### U.S. incidence, all colorectal cancer stages

> “The rate of new cases of colorectal cancer was 37.6 per 100,000 men and women per year.”

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/colorect.html)

<a id="topic-2.2.1.2.1-2"></a>

###### Estimated U.S. new cases in 2026, all colorectal cancer stages

> “There will be an estimated 158,850 new cases of CRC in the United States in 2026”

Source: [American Cancer Society (2026)](https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.70067)

<a id="topic-2.2.1.2.1-3"></a>

###### Distant-stage disease at diagnosis

| SEER measure | Direct quotation |
| --- | --- |
| Percentage diagnosed at distant stage | “23%” |

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/colorect.html)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Metastatic colorectal cancer

<a id="topic-2.2.1.2.2-1"></a>

###### U.S. prevalence in 2023, all colorectal cancer stages

> “In 2023, there were an estimated 1,478,528 people living with colorectal cancer in the United States.”

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/colorect.html)

<a id="topic-2.2.1.2.2-2"></a>

###### Metastatic-specific prevalence

No evidence found.

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Distant-stage five-year relative survival

| SEER measure | Direct quotation |
| --- | --- |
| Distant-stage five-year relative survival | “16.9%” |

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/colorect.html)

<a id="topic-2.2.1.3-2"></a>

###### Estimated U.S. deaths in 2026, all colorectal cancer stages

| Measure | Quoted value |
| --- | --- |
| Deaths | “55,230” |

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/colorect.html)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Progression from colorectal polyps

> “Sometimes abnormal growths, called polyps, form in the colon or rectum. Over time, some polyps may turn into cancer.”

Source: [Centers for Disease Control and Prevention about colorectal cancer page](https://www.cdc.gov/colorectal-cancer/about/index.html)

Additional sources: [Ashouri et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12719898/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Guideline-recommended molecular assessment at metastatic diagnosis

| Assessment | Quoted biomarker |
| --- | --- |
| Mismatch-repair testing | “MMR” |
| RAS mutation testing | “KRAS” |
| RAS mutation testing | “NRAS” |
| BRAF mutation testing | “BRAF” |

Source: [Yoshino et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10220270/)

Additional sources: [Yoshino et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37236086/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Bowel symptoms: change in bowel habits

> “A change in bowel habits.”

Source: [Centers for Disease Control and Prevention colorectal cancer symptoms page](https://www.cdc.gov/colorectal-cancer/symptoms/index.html)

<a id="topic-2.2.1.6-2"></a>

###### Bleeding: blood in the stool

> “Blood in or on your stool (bowel movement).”

Source: [Centers for Disease Control and Prevention colorectal cancer symptoms page](https://www.cdc.gov/colorectal-cancer/symptoms/index.html)

<a id="topic-2.2.1.6-3"></a>

###### Pain: persistent abdominal symptoms

> “Abdominal pain, aches, or cramps that don't go away.”

Source: [Centers for Disease Control and Prevention colorectal cancer symptoms page](https://www.cdc.gov/colorectal-cancer/symptoms/index.html)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

No evidence found.

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Metastatic colorectal cancer

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Comparator and disease-state studies: third-line treatment decision-making among community physicians

> “Overall survival (OS) and impacts to patient quality of life (QoL) were primary considerations for any third-line treatment for mCRC.”

Source: [Cann et al. (2026)](https://profiles.foxchase.org/en/publications/third-line-treatment-decision-making-for-metastatic-colorectal-ca/)

<a id="topic-2.2.1.8.1-2"></a>

###### Comparator and disease-state studies: SUNLIGHT health-related quality of life and performance status

> “Both treatment arms showed similar QoL scores from baseline to cycle 6, with no clinically relevant change over time.”

Source: [Taieb et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39818468/)

<a id="topic-2.2.1.8.1-3"></a>

###### Comparator and disease-state studies: FRESCO-2 quality-adjusted survival

> “Fruquintinib provides a clinically meaningful quality-adjusted survival benefit versus placebo in refractory mCRC.”

Source: [Stintzing et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11904580/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Metastatic colorectal cancer treatment costs: systematic review

> “Costs of treating metastatic colorectal cancer varied because of the heterogeneity of treatment.”
> “Studies reported average costs ranged from $12,346 to $293,461.”

Source: [Bhimani et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36063775/)

<a id="topic-2.2.1.8.2-2"></a>

###### Cost concentration in regimens containing biological agents

> “Studies that treated patients with biological agents demonstrated costs ranging from $80,000 to almost $300,000.”
> “The studies included in this systematic review demonstrate a rising cost of treating mCRC over the past 20 years.”
> “the economic burden of treating patients with mCRC is substantial, particularly after the introduction of expensive biological agents such as cetuximab, bevacizumab, and panitumumab.”

Source: [Bhimani et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36063775/)

<a id="topic-2.2.1.8.2-3"></a>

###### Major financial hardship in metastatic colorectal cancer

> “Cumulative incidence of MFH at 12 months was 71.3% (95% confidence interval = 65.7% to 76.1%).”
> “A total of 380 patients (median age = 59.9 years) were enrolled; 77.7% were White, 98.0% insured, and 56.5% had annual income of $50 000 or less.”

Source: [Shankaran et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8902339/)

<a id="topic-2.2.1.8.2-4"></a>

###### Comparator and disease-state studies: third-line treatment discontinuation and cost effectiveness

> “Among 82 patients”
> “Analyses were conducted from the US Medicare payer perspective”
> “The ICER was US$518,000 per QALY gained.”

Source: [Kiel et al. (2026)](https://link.springer.com/article/10.1007/s40801-026-00539-9)

Additional sources: [Paly et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38976346/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Metastatic colorectal cancer on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Patient-reported household financial hardship at 12 months

| Financial hardship component | Cumulative incidence |
| --- | --- |
| Income decline of at least 20% | “26.6%” |
| Loans from family or friends | “26.0%” |

Source: [Shankaran et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8902339/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### KRAS and BRAF predictive testing before cetuximab: Swiss economic model

> “KRAS/BRAF testing was the most cost-effective approach when compared with the reference strategy (incremental cost-effectiveness ratio: €62,653/QALY).”

Source: [Blank et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21807639/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Cytotoxic Chemotherapy

<a id="topic-2.2.2.1.1-1"></a>

###### First-line cytotoxic chemotherapy backbones

> “FOLFOX or FOLFIRI”

Source: [National Cancer Institute Colon Cancer Treatment PDQ](https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq)

Additional sources: [Prager et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37133585/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 VEGF-pathway Antibodies and Fusion Proteins

<a id="topic-2.2.2.1.2-1"></a>

###### First-line bevacizumab with cytotoxic chemotherapy

> “Bevacizumab can reasonably be added to either FOLFIRI or FOLFOX”

Source: [National Cancer Institute Colon Cancer Treatment PDQ](https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq)

<a id="topic-2.2.2.1.2-2"></a>

###### Approved treatment alternatives: trifluridine/tipiracil plus bevacizumab

> “On August 2, 2023, the Food and Drug Administration approved trifluridine and tipiracil (LONSURF, Taiho Oncology, Inc.) with bevacizumab, for metastatic colorectal cancer”

Source: [FDA trifluridine and tipiracil with bevacizumab approval announcement (2023)](https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-trifluridine-and-tipiracil-bevacizumab-previously-treated-metastatic-colorectal-cancer)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 EGFR Monoclonal Antibodies

<a id="topic-2.2.2.1.3-1"></a>

###### Biomarker-directed treatment recommendations

> “Anti-EGFR therapy is not recommended for patients with RAS-mutant mCRC.”

Source: [ASCO (2022)](https://ascopubs.org/doi/10.1200/JCO.22.01690)

<a id="topic-2.2.2.1.3-2"></a>

###### Population recommended for first-line anti-EGFR therapy plus doublet chemotherapy

> “MSS or pMMR left-sided RAS wild-type mCRC”

Source: [Morris et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506310/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Immune Checkpoint Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### Biomarker-directed treatment recommendations

> “Pembrolizumab should be offered as first-line therapy to patients with MSI-H or dMMR mCRC”

Source: [ASCO (2022)](https://ascopubs.org/doi/10.1200/JCO.22.01690)

<a id="topic-2.2.2.1.4-2"></a>

###### Nivolumab plus ipilimumab: FDA-approved disease subgroup

> “unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).”

Source: [FDA nivolumab with ipilimumab approval announcement (2025)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 VEGFR and Multikinase Inhibitors

<a id="topic-2.2.2.1.5-1"></a>

###### Regorafenib placement in therapy

> “regorafenib is now often considered a fourth-line or later option for treatment of patients with metastatic colorectal cancer.”

Source: [National Cancer Institute Colon Cancer Treatment PDQ](https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq)

<a id="topic-2.2.2.1.5-2"></a>

###### Approved treatment alternatives: fruquintinib

> “On November 8, 2023, the Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) for adult patients with metastatic colorectal cancer (mCRC)”

Source: [FDA fruquintinib approval announcement (2023)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fruquintinib-refractory-metastatic-colorectal-cancer)

<a id="topic-2.2.2.1.5-3"></a>

###### Comparator pivotal publication: FRESCO-2

> “Median overall survival was 7·4 months (95% CI 6·7-8·2) in the fruquintinib group versus 4·8 months (4·0-5·8) in the placebo group”

Source: [Dasari et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37331369/)

<a id="topic-2.2.2.1.5-4"></a>

###### Comparator pivotal publication: CORRECT overall survival

> “Median overall survival was 6·4 months in the regorafenib group versus 5·0 months in the placebo group (hazard ratio 0·77; 95% CI 0·64–0·94; one-sided p=0·0052).”
> “Regorafenib is the first small-molecule multikinase inhibitor with survival benefits in metastatic colorectal cancer which has progressed after all standard therapies.”

Source: [Grothey et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23177514/)

<a id="topic-2.2.2.1.5-5"></a>

###### Comparator pivotal publication: CORRECT toxicity

> “Treatment-related adverse events occurred in 465 (93%) patients assigned regorafenib and in 154 (61%) of those assigned placebo.”
> “The most common adverse events of grade three or higher related to regorafenib were hand-foot skin reaction (83 patients, 17%), fatigue (48, 10%), diarrhoea (36, 7%), hypertension (36, 7%), and rash or desquamation (29, 6%).”

Source: [Grothey et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23177514/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 BRAF-directed Combination Therapy

<a id="topic-2.2.2.1.6-1"></a>

###### Encorafenib traditional approval: combination and biomarker requirements

> “in combination with cetuximab and fluorouracil-based chemotherapy”
> “with a BRAF V600E mutation, as detected by an FDA-authorized test.”

Source: [FDA (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-encorafenib-metastatic-colorectal-cancer-braf-v600e-mutation)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 HER2-directed Therapy

<a id="topic-2.2.2.1.7-1"></a>

###### Tucatinib with trastuzumab after prior chemotherapy

> “in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer”

Source: [FDA tucatinib with trastuzumab accelerated approval announcement (2023)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 KRAS G12C-directed Combination Therapy

<a id="topic-2.2.2.1.8-1"></a>

###### Sotorasib plus panitumumab: disease subgroup and prior therapy

> “KRAS G12C-mutated metastatic colorectal cancer (mCRC)”
> “who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.”

Source: [FDA sotorasib with panitumumab approval announcement (2025)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sotorasib-panitumumab-kras-g12c-mutated-colorectal-cancer)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 NTRK Inhibitors

<a id="topic-2.2.2.1.9-1"></a>

###### Therapies recommended for an NTRK fusion

> “larotrectinib or entrectinib”

Source: [Yoshino et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10220270/)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Surgical Resection

<a id="topic-2.2.2.1.10-1"></a>

###### Potentially curative liver-metastasis resection

> “candidates for potentially curative resection of liver metastases”

Source: [Morris et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506310/)

<a id="heading-2.2.2.1.11"></a>

###### 2.2.2.1.11 Thermal Ablation

<a id="topic-2.2.2.1.11-1"></a>

###### Small liver metastases in selected unresectable or oligometastatic disease

> “TA can be considered for small metastases”

Source: [Yoshino et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10220270/)

<a id="heading-2.2.2.1.12"></a>

###### 2.2.2.1.12 Stereotactic Body Radiotherapy

<a id="topic-2.2.2.1.12-1"></a>

###### Guideline-supported radiotherapy option

> “SBRT is a treatment option”

Source: [Yoshino et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10220270/)

<a id="heading-2.2.2.1.13"></a>

###### 2.2.2.1.13 Intra-arterial Therapies

<a id="topic-2.2.2.1.13-1"></a>

###### Non-curative intra-arterial options in expert centres

> “TACE, TARE/SIRT and HAIC”

Source: [Yoshino et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10220270/)

<a id="heading-2.2.2.1.14"></a>

###### 2.2.2.1.14 Limitations of Current Therapies

<a id="topic-2.2.2.1.14-1"></a>

###### Summary

Available treatments depend on molecular subtype, prior therapy, and resectability. ASCO recommends first-line pembrolizumab for MSI-H or dMMR disease but does not recommend anti-EGFR therapy for RAS-mutant disease. A systematic review of 53 clinical trials reported limited activity for checkpoint-inhibitor monotherapy or checkpoint-inhibitor combinations in MSS colorectal cancer. The LEAP-017 and IMblaze370 trials did not establish their specified overall-survival benefits. These findings limit extrapolation between biomarker groups and between different kinase-inhibitor and immunotherapy combinations.

Source: [ASCO (2022)](https://ascopubs.org/doi/10.1200/JCO.22.01690); [Guven et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11067816/); [Kawazoe et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11328923/); [Eng et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31003911/)

<a id="topic-2.2.2.1.14-2"></a>

###### Unmet treatment need

> “Most patients with metastatic colorectal cancer (mCRC) have limited treatment options following standard-of-care therapy.”

Source: [Saeed et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11485978/)

<a id="topic-2.2.2.1.14-3"></a>

###### Immune checkpoint inhibitors in microsatellite-stable colorectal cancer: systematic review

> “53 clinical trials included in the review.”
> “ICI monotherapy or ICI-ICI combinations demonstrated limited clinical activity for patients with MSS CRC”

Source: [Guven et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11067816/)

Additional sources: [Rasschaert and Tejpar (2025)](https://pubmed.ncbi.nlm.nih.gov/41241502/); [Burge et al. (2026)](https://doi.org/10.1016/j.clcc.2026.04.001)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The proposed population comprises adults previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with prior anti-EGFR therapy for RAS wild-type disease. The pivotal regimen combines daily oral zanzalintinib with intravenous atezolizumab every three weeks. This is an investigational treatment position, not an approved prescribing recommendation or established commercial access pathway.

Source: [Exelixis new drug application acceptance announcement (2026)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-us-fda-accepted-new-drug-application); [ASCO (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.TPS3630); [Exelixis STELLAR-303 update announcement (2026)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-provides-update-phase-3-stellar-303-trial-evaluating)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### STELLAR-303 overall-survival subgroup estimates at the initial reported analysis

| Subgroup | Hazard ratio and 95% confidence interval |
| --- | --- |
| RAS wild type | “0.79 (0.61-1.01)” |
| RAS mutant | “0.80 (0.66-0.98)” |

Source: [Exelixis STELLAR-303 detailed results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-detailed-results-phase-3-stellar-303-pivotal)

<a id="topic-2.2.2.3-2"></a>

###### Final overall-survival analysis without active liver metastases

> “non-statistically significant”
> “stratified hazard ratio: 0.83; 95% confidence interval: 0.66–1.05; P=0.1185”

Source: [Exelixis STELLAR-303 update announcement (2026)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-provides-update-phase-3-stellar-303-trial-evaluating)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Shared decision making

> “Shared decision making is recommended”

Source: [Morris et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506310/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Pivotal trial overall-survival target

> “OS in the ITT population and in the NLM subgroup of patients.”

Source: [Exelixis STELLAR-303 topline results announcement (2025)](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-zanzalintinib-combination-immune-checkpoint)

## Related pages
- [Zanzalintinib (XL092): Metastatic colorectal cancer](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: Terms and abbreviations](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/terms-and-abbreviations.md)
- [Zanzalintinib (XL092): Metastatic colorectal cancer](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/executive-summary.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: Clinical evidence](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/clinical-evidence.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: Economic information and modeling report](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/economics.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: References](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/references) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/references.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: prevalence by geography](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/prevalence.md)
- [Zanzalintinib (XL092) in Metastatic colorectal cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/cost-effectiveness-analyses.md)
